Literature DB >> 12145558

Protective effects of anti-neutrophil antibody against myocardial ischemia/reperfusion injury in rats.

T Kohtani1, Y Abe, M Sato, K Miyauchi, K Kawachi.   

Abstract

Neutrophil activation initiates myocardial ischemia/reperfusion (I/R) injuries. The aim of this study is to evaluate the in vitro functions of an anti-neutrophil monoclonal antibody, Urge-8, and its therapeutic efficacy against myocardial ischemia (MI) in rats. We measured in vitro functions of rat neutrophils including chemotactic activity, superoxide production, phagocytic function, and neutrophil degranulation. MI was induced in Wistar rats by clamping the left coronary artery for 1 h. Rats received either isotype-negative control IgG(1) (control group, n = 20), 250 microg/kg of Urge-8 before (pre-treatment group, n = 20) or after (post-treatment group, n = 20) MI. The three groups were compared during the first 24 h after reperfusion with respect to changes in mean arterial pressure, heart rate, body temperature, biochemistry, serum cytokines, myocardial neutrophil infiltration, survival rate, and size of MI. Urge-8 effectively suppressed in vitro functions of rat neutrophils including chemotactic activity, superoxide production, phagocytic function, and neutrophil degranulation. The Urge-8 treated groups showed higher levels of arterial pressure and survival rate, lower values of interleukin-6 and interleukin-8, lower grade of myocardial neutrophil infiltration, and smaller MI size as compared to the control group. In conclusion, Urge-8 is effective against myocardial I/R injury by suppressing certain functions and myocardial infiltration of neutrophils in rats. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12145558     DOI: 10.1159/000063073

Source DB:  PubMed          Journal:  Eur Surg Res        ISSN: 0014-312X            Impact factor:   1.745


  7 in total

1.  Repertaxin, a novel inhibitor of rat CXCR2 function, inhibits inflammatory responses that follow intestinal ischaemia and reperfusion injury.

Authors:  Danielle G Souza; Riccardo Bertini; Angelica T Vieira; Fernando Q Cunha; Steve Poole; Marcello Allegretti; Francesco Colotta; Mauro M Teixeira
Journal:  Br J Pharmacol       Date:  2004-08-09       Impact factor: 8.739

2.  APT070 (Mirococept), a membrane-localised complement inhibitor, inhibits inflammatory responses that follow intestinal ischaemia and reperfusion injury.

Authors:  Danielle G Souza; Dirk Esser; Roberta Bradford; Angélica T Vieira; Mauro M Teixeira
Journal:  Br J Pharmacol       Date:  2005-08       Impact factor: 8.739

Review 3.  Immune cells as targets for cardioprotection: new players and novel therapeutic opportunities.

Authors:  Ioanna Andreadou; Hector A Cabrera-Fuentes; Yvan Devaux; Nikolaos G Frangogiannis; Stefan Frantz; Tomasz Guzik; Elisa A Liehn; Clarissa P C Gomes; Rainer Schulz; Derek J Hausenloy
Journal:  Cardiovasc Res       Date:  2019-06-01       Impact factor: 10.787

4.  5'- Adenosine monophosphate induced hypothermia reduces early stage myocardial ischemia/reperfusion injury in a mouse model.

Authors:  Zhenyin Tao; Zhaoyang Zhao; Cheng Chi Lee
Journal:  Am J Transl Res       Date:  2011-07-18       Impact factor: 4.060

5.  Depletion of intestinal resident macrophages prevents ischaemia reperfusion injury in gut.

Authors:  Y Chen; V C H Lui; N V Rooijen; P K H Tam
Journal:  Gut       Date:  2004-12       Impact factor: 23.059

Review 6.  Efferocytosis and Outside-In Signaling by Cardiac Phagocytes. Links to Repair, Cellular Programming, and Intercellular Crosstalk in Heart.

Authors:  Matthew DeBerge; Shuang Zhang; Kristofor Glinton; Luba Grigoryeva; Islam Hussein; Esther Vorovich; Karen Ho; Xunrong Luo; Edward B Thorp
Journal:  Front Immunol       Date:  2017-11-01       Impact factor: 7.561

7.  Ticagrelor attenuates myocardial ischaemia-reperfusion injury possibly through downregulating galectin-3 expression in the infarct area of rats.

Authors:  Xiaogang Liu; Ye Gu; Yufeng Liu; Mingjing Zhang; Yuting Wang; Liqun Hu
Journal:  Br J Clin Pharmacol       Date:  2018-03-09       Impact factor: 4.335

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.